

GENERAL ASSEMBLY OF NORTH CAROLINA  
SESSION 2009

H

D

HOUSE DRH80096-LN-97 (2/26)

Short Title: Cancer Drug Coverage Changes.

(Public)

Sponsors: Representative Harrell.

Referred to:

1 A BILL TO BE ENTITLED  
2 AN ACT TO UPDATE THE CANCER COMPENDIA STATUTE TO REFLECT NEW  
3 COMPENDIA THAT ARE AVAILABLE.

4 The General Assembly of North Carolina enacts:

5 SECTION 1. G.S. 58-51-59 reads as rewritten:

6 "§ 58-51-59. Coverage of certain prescribed drugs for cancer treatment.

7 (a) No policy or contract of accident or health insurance, and no preferred provider  
8 benefit plan under G.S. 58-50-56, that is issued, renewed, or amended on or after January 1,  
9 1994, and that provides coverage for prescribed drugs approved by the federal Food and Drug  
10 Administration for the treatment of certain types of cancer shall exclude coverage of any drug  
11 on the basis that the drug has been prescribed for the treatment of a type of cancer for which the  
12 drug has not been approved by the federal Food and Drug Administration. The drug, however,  
13 must be approved by the federal Food and Drug Administration and must have been proven  
14 effective and accepted for the treatment of the specific type of cancer for which the drug has  
15 been prescribed in any one of the following established reference compendia:

- 16 (1) ~~The American Medical Association Drug Evaluations;~~ The National  
17 Comprehensive Cancer Network Drugs & Biologics Compendium;  
18 (2) ~~The American Hospital Formulary Service Drug Information; or The~~  
19 ThomsonMicromedex DrugDex;  
20 (3) ~~The United States Pharmacopeia Drug Information.~~ The Elsevier Gold  
21 Standard's Clinical Pharmacology; or  
22 (4) Any other authoritative compendia as recognized periodically by the United  
23 States Secretary of Health and Human Services.

24 (b) Notwithstanding subsection (a) of this section, coverage shall not be required for  
25 any experimental or investigational drugs or any drug that the federal Food and Drug  
26 Administration has determined to be contraindicated for treatment of the specific type of cancer  
27 for which the drug has been prescribed.

28 (c) This section shall apply only to cancer drugs and nothing in this section shall be  
29 construed, expressly or by implication, to create, impair, alter, limit, notify, enlarge, abrogate,  
30 or prohibit reimbursement for drugs used in the treatment of any other disease or condition."

31 SECTION 2. G.S. 58-65-94 reads as rewritten:

32 "§ 58-65-94. Coverage of certain prescribed drugs for cancer treatment.

33 (a) No insurance certificate or subscriber contract under any hospital service plan or  
34 medical service plan governed by this Article and Article 66 of this Chapter, and no preferred  
35 provider benefit plan under G.S. 58-50-56, that is issued, renewed, or amended on or after



1 January 1, 1994, and that provides coverage for prescribed drugs approved by the federal Food  
2 and Drug Administration for the treatment of certain types of cancer shall exclude coverage of  
3 any drug on the basis that the drug has been prescribed for the treatment of a type of cancer for  
4 which the drug has not been approved by the federal Food and Drug Administration. The drug,  
5 however, must be approved by the federal Food and Drug Administration and must have been  
6 proven effective and accepted for the treatment of the specific type of cancer for which the drug  
7 has been prescribed in any one of the following established reference compendia:

- 8 (1) ~~The American Medical Association Drug Evaluations; The National~~  
9 ~~Comprehensive Cancer Network Drugs & Biologics Compendium;~~
- 10 (2) ~~The American Hospital Formulary Service Drug Information; or The~~  
11 ~~ThomsonMicromedex DrugDex;~~
- 12 (3) ~~The United States Pharmacopeia Drug Information. The Elsevier Gold~~  
13 ~~Standard's Clinical Pharmacology; or~~
- 14 (4) Any other authoritative compendia as recognized periodically by the United  
15 States Secretary of Health and Human Services.

16 (b) Notwithstanding subsection (a) of this section, coverage shall not be required for  
17 any experimental or investigational drugs or any drug that the federal Food and Drug  
18 Administration has determined to be contraindicated for treatment of the specific type of cancer  
19 for which the drug has been prescribed.

20 (c) This section shall apply only to cancer drugs and nothing in this section shall be  
21 construed, expressly or by implication, to create, impair, alter, limit, notify, enlarge, abrogate,  
22 or prohibit reimbursement for drugs used in the treatment of any other disease or condition."

23 **SECTION 3.** G.S. 58-67-78 reads as rewritten:

24 "**§ 58-67-78. Coverage of certain prescribed drugs for cancer treatment.**

25 (a) No health care plan written by a health maintenance organization and in force,  
26 issued, renewed, or amended on or after January 1, 1994, and that provides coverage for  
27 prescribed drugs approved by the federal Food and Drug Administration for the treatment of  
28 certain types of cancer shall exclude coverage of any drug on the basis that the drug has been  
29 prescribed for the treatment of a type of cancer for which the drug has not been approved by the  
30 federal Food and Drug Administration. The drug, however, must be approved by the federal  
31 Food and Drug Administration and must have been proven effective and accepted for the  
32 treatment of the specific type of cancer for which the drug has been prescribed in any one of the  
33 following established reference compendia:

- 34 (1) ~~The American Medical Association Drug Evaluations; The National~~  
35 ~~Comprehensive Cancer Network Drugs & Biologics Compendium;~~
- 36 (2) ~~The American Hospital Formulary Service Drug Information; or The~~  
37 ~~ThomsonMicromedex DrugDex;~~
- 38 (3) ~~The United States Pharmacopeia Drug Information. The Elsevier Gold~~  
39 ~~Standard's Clinical Pharmacology; or~~
- 40 (4) Any other authoritative compendia as recognized periodically by the United  
41 States Secretary of Health and Human Services.

42 (b) Notwithstanding subsection (a) of this section, coverage shall not be required for  
43 any experimental or investigational drugs or any drug that the federal Food and Drug  
44 Administration has determined to be contraindicated for treatment of the specific type of cancer  
45 for which the drug has been prescribed.

46 (c) This section shall apply only to cancer drugs and nothing in this section shall be  
47 construed, expressly or by implication, to create, impair, alter, limit, notify, enlarge, abrogate,  
48 or prohibit reimbursement for drugs used in the treatment of any other disease or condition."

49 **SECTION 4.** This act is effective when it becomes law.